Exclusive: National Vision CEO on transformation, margins, and growth

Managed care now represents nearly 42% of National Vision's sales, driving higher average tickets and margin expansion: Q4 gross margin widened ~40 bps and operating margin expanded 160 bps YoY in fiscal 2025, with management targeting an additional 50–150 bps of operating margin improvement from 2026–2030. The rollout of smart eyewear (Ray‑Ban Meta into >1,200 stores), premium assortment targets (60% premium frames by end‑2026), tech upgrades and a modest plan for 30–35 new stores this year support continued revenue and profitability upside; shares are up ~120% over the past 12 months after consistent beats.

Analysis

EYE’s strategic tilt toward higher‑ticket customers and smart eyewear is less a retail play than a transformation of revenue mix and working‑capital dynamics. Higher average sale values magnify receivables and claim adjudication exposure to payors — meaning a material portion of future margin improvement depends on payer pricing stability and administrative throughput rather than pure retail execution.

A second‑order constraint is supply chain and service capacity: premium frames, premium lens processing and authenticated smart‑glass SKUs require tighter lab capacity, higher inventory carrying, and closer vendor SLAs. If attach rates scale faster than lab throughput, margin dollars will be capped by slot availability and incremental freight/capex to expand finishing capacity, not by consumer demand.

Key catalysts live on three horizons: near‑term quarterly results that reveal same‑store margin dollars and attach‑rate trends; medium‑term contract renewals with managed‑care payors that can reprice economics within 6–24 months; and a multi‑year technology/store modernization that de‑risks scaling but front‑loads capex. The asymmetric outcome is clear — successful execution leverages operating fixed costs into outsized EBITDA growth, while execution missteps (payor repricing, lab bottlenecks, or slower smart‑eyewear adoption) create sharp margin reversals.

Key Decisions for Investors

• Long EYE equity (size 2–4% portfolio) with a 12‑month horizon: enter on any pullback >10% from current levels; target 30–50% total return if margin dollars and attach‑rates continue to inflect; hard stop at 15% below entry to limit downside from payor or execution shocks.
• Buy a cost‑effective call spread on EYE to capture multi‑quarter execution upside: buy 12–18 month calls 25% OTM and sell 60% OTM (or adjust strikes to net debit ≈40–60% of outright long). Rationale: asymmetric upside if margins scale while capping premium paid if smart‑eyewear adoption lags.
• Pair trade: long EYE / short XRT (equal $ exposure) over 6–12 months to isolate company‑specific mix improvement from broad retail cyclicality. Risk/reward: outperformance if EYE converts higher AOV into operating leverage; underperformance if consumer discretionary spending rebounds broadly and benefits peers more.
• Tactical exposure to smart‑eyewear ecosystem: buy moderate‑duration calls on META (6–12 months) sized <1% portfolio to play structural demand for connected eyewear and software services; payoff asymmetric if adoption accelerates into holiday cadence but limited by platform concentration and regulatory scrutiny risks.